262 research outputs found
O PASS-THROUGH DAS VARIAÇÕES DA TAXA DE CÂMBIO PARA OS PREÇOS DE EXPORTAÇÃO DE SOJA
Este trabalho tem como objetivo estimar o coeficiente de pass-through das variações da taxa de câmbio para os preços de exportação da soja no Brasil, no período compreendido entre 1994 a 2004. Para chegar aos resultados utilizou-se econometria de séries de tempo para mensurar os coeficientes de pass-through da taxa de câmbio para os preços de exportação. O resultado revelou um grau de pass-through incompleto, da ordem de -0,34, indicando que a política cambial pode ocasionar impactos positivos sobre o volume das exportações, mas, não deve ser a única política de estímulo.The objective of this work is to assess the pass-through coefficient of the exchange rate variations for the export prices of soybeans in Brazil, in the period comprised between 1994 and 2004. Time series econometrics was used in order to obtain the results to measure the pass-through coefficients of the exchange rate for the export prices. The result demonstrate a non-complete pass-through rate circa - 0,34, showing that exchange policy may cause positive impacts on the exportation amounts, however, it should not be the only motivation
policy
POLAR registry (Promus eluting stent registry in Latin America ):1 year follow-up results
BACKGROUND: Drug-eluting stents have been used since 2002 in different patient populations aiming to achieve high success rates with low clinical and angiographic restenosis rates. With the late thrombosis adverse events associated to the first generation sirolimus and paclitaxel-eluting stents, second-generation everolimus and zotarolimus-eluting stents has been recently developed. METHODS: The POLAR registry is a prospective, non-randomized, multicenter study, which included 988 patients, totaling 1,362 lesions treated with the everolimus-eluting stent Promus®. In order to represent the clinical practice, almost all subtypes of patients and lesions were included in this registry. Clinical follow-up was planned to be performed 1, 6, 12 and 24 months after the procedure. RESULTS: Most patients were male (69.8%), with mean age of 64.9 ± 9.4 years, 35.2% were diabetics and 55% had been treated for acute coronary syndrome. Vessel diameter was 2.95 ± 0.43 mm and lesion extension was 20.5 ± 5.6 mm. A total of 1.14 ± 0.38 stent/patient were implanted and the procedural success rate was 96.6%. Major adverse cardiac events occurred in 4.5% of patients, and stent thrombosis was observed in 5 patients (0.5%) after a clinical follow-up of 12 months. CONCLUSIONS: The present registry suggests that everolimus-eluting stents are safe and effective in daily clinical practice patients, with a low rate of major adverse cardiac events at the end of the first year of follow-up.INTRODUÇÃO: Desde 2002, os stents farmacológicos são utilizados em diversas populações de pacientes objetivando alcançar elevados índices de sucesso, com baixas taxas de reestenose angiográfica e clínica. Com os resultados adversos em relação à trombose tardia associados aos stents farmacológicos de primeira geração eluidores de sirolimus e paclitaxel, surgiram recentemente os stents farmacológicos de segunda geração eluidores de zotarolimus e everolimus. MÉTODOS: O registro POLAR é um registro prospectivo, não-randomizado, multicêntrico, que incluiu 988 pacientes totalizando 1.362 lesões tratadas com o stent Promus®. Objetivando representar a prática clínica, praticamente todos os subtipos de pacientes e lesões foram incluídos neste registro. O seguimento clínico foi planejado para ser realizado 1 mês, 6 meses, 12 meses e 24 meses após o procedimento. RESULTADOS: A maioria dos pacientes era do sexo masculino (69,8%), com média de idade de 64,9 ± 9,4 anos, 35,2% eram diabéticos e 55% tinham sido tratados na vigência de síndrome coronária aguda. O diâmetro do vaso foi de 2,95 ± 0,43 mm e a extensão da lesão, de 20,5 ± 5,6 mm. Foi implantado 1,14 ± 0,38 stent/paciente e o sucesso do procedimento foi alcançado em 96,6% dos casos. Eventos cardíacos adversos maiores ocorreram em 4,1% dos pacientes, e trombose de stent esteve presente em 5 pacientes (0,5%) após o seguimento clínico de 12 meses. CONCLUSÕES: O presente registro sugere que os stents farmacológicos eluidores de everolimus são seguros e eficazes em pacientes da prática clínica diária, com baixas taxas de eventos cardíacos adversos maiores ao término do primeiro ano de seguimento.Universidade Federal de São Paulo (UNIFESP)Instituto Dante Pazzanese de CardiologiaStatus CorHospital Israelita Albert EinsteinENCORE Hospital Lúcio RebeloReal e Benemérita Associação Portuguesa de BeneficênciaHospital Cardiológico CostantiniHemodinâmica Meridional Intercath MeridionalInstituto de Cardiologia do Espírito SantoFundação Universitária de Cardiologia Instituto de Cardiologia do Rio Grande do SulUNIFESPSciEL
Efeito do Levamisole sobre a resposta imunitária de cobaias tratados com vacina antiaftosa inativada
The protection titer of an inactivated tricalent “O", “A" and “C” Foot-and-Mouth disease (FMD) vaccine was assayed in two groups of 96 guinea pigs, one of them received levamisole at an animal daily dose of 2,5 mg/kg during the three days starting the day of the FMD vaccination and the other one was used as control. The range of vaccine dilutions was 10-0, OOO, 10-602, 10-1, 204 e 10-1,806 and animals were challenged at 21 days after vaccination with 158 DG50 of FMD virus type “C” Waldmann. Although no significant difference was detected between the protection vaccine titer of the two groups, a paired analysis of each vaccine dilution result revealed a favorable effect of levamisole when the vaccine was used at a dilution 10-1,806 .O título de proteção de uma vacina antiaftosa trivalente (O-A-C) inativada foi restabelecido em dois grupos de 96 cobaios, um dos quais recebeu Levamisole na dose diária de 2,5 miligramas por quilo durante três dias consecutivos a partir do momento da vacinação e o outro foi utilizado como controle. A vacina foi empregada nas diluições 10-0, OOO, 10-602, 10-1, 204 e 10-1,806 e os animais desafiados aos 21 dias após a vacinação com 158 DG50 do vírus “C” Waldmann da febre aftosa. Embora não tenha sido verificada uma diferença significante entre os títulos de proteção da vacina nos dois grupos, uma análise pareada dos valores obtidos com cada uma das diluições da vacina revelou um efeito favorável do Levamisole apenas quando a vacina foi empregada na diluição 10-1,806
Immunodominant Antigens of Leishmania chagasi Associated with Protection against Human Visceral Leishmaniasis
One of the most striking features of infection by Leishmania chagasi is that infection leads to a spectrum of clinical outcomes ranging from asymptomatic infection to active disease. The existence of asymptomatic infected people has served as an incentive to believe that an effective vaccine is possible, but unfortunately no successful immunological characterization of such cases was obtained. Patients recovered from visceral leishmaniasis show a similar immunological profile to asymptomatic infected individuals and both exhibit a strong cell-mediated immune response against Leishmania antigens and are resistant to disease. Since the past decade several approaches were undertaken to try to shed light on the immunological profile associated with such “resistance” to infections, notwithstanding antigenic recognition profile associated to resistance to infection was not successfully explored. In the present manuscript we describe a specific IgG recognizing pattern associated with resistant individuals (asymptomatic infected people and recovery patients to visceral leishmaniasis). These data highlight the possibility of using specific proteins in serological tests for the identification of asymptomatic infected individuals
Maternal LAMP/p55gagHIV-1 DNA Immunization Induces In Utero Priming and a Long-Lasting Immune Response in Vaccinated Neonates
Infants born to HIV-infected mothers are at high risk of becoming infected during gestation or the breastfeeding period. A search is thus warranted for vaccine formulations that will prevent mother-to-child HIV transmission. The LAMP/gag DNA chimeric vaccine encodes the HIV-1 p55gag fused to the lysosome-associated membrane protein-1 (LAMP-1) and has been shown to enhance anti-Gag antibody (Ab) and cellular immune responses in adult and neonatal mice; such a vaccine represents a new concept in antigen presentation. In this study, we evaluated the effect of LAMP/gag DNA immunization on neonates either before conception or during pregnancy. LAMP/gag immunization of BALB/c mice before conception by the intradermal route led to the transfer of anti-Gag IgG1 Ab through the placenta and via breastfeeding. Furthermore, there were an increased percentage of CD4+CD25+Foxp3+T cells in the spleens of neonates. When offspring were immunized with LAMP/gag DNA, the anti-Gag Ab response and the Gag-specific IFN-γ-secreting cells were decreased. Inhibition of anti-Gag Ab production and cellular responses were not observed six months after immunization, indicating that maternal immunization did not interfere with the long-lasting memory response in offspring. Injection of purified IgG in conjunction with LAMP/gag DNA immunization decreased humoral and cytotoxic T-cell responses. LAMP/gag DNA immunization by intradermal injection prior to conception promoted the transfer of Ab, leading to a diminished response to Gag without interfering with the development of anti-Gag T- and B-cell memory. Finally, we assessed responses after one intravenous injection of LAMP/gag DNA during the last five days of pregnancy. The intravenous injection led to in utero immunization. In conclusion, DNA vaccine enconding LAMP-1 with Gag and other HIV-1 antigens should be considered in the development of a protective vaccine for the maternal/fetal and newborn periods
Detection of Human Bocavirus mRNA in Respiratory Secretions Correlates with High Viral Load and Concurrent Diarrhea
Human bocavirus (HBoV) is a parvovirus recently identified in association with acute respiratory infections (ARI). Despite its worldwide occurrence, little is known on the pathogenesis of HBoV infections. In addition, few systematic studies of HBoV in ARI have been conducted in Latin America. Therefore, in order to test whether active viral replication of human bocavirus is associated with respiratory diseases and to understand the clinical impact of this virus in patients with these diseases, we performed a 3-year retrospective hospital-based study of HBoV in outpatients and inpatients with symptoms of Acute Respiratory Infections (ARI) in Brazil. Nasopharyngeal aspirates (NPAs) from 1015 patients with respiratory symptoms were tested for HBoV DNA by PCR. All samples positive for HBoV were tested by PCR for all other respiratory viruses, had HBoV viral loads determined by quantitative real time PCR and, when possible, were tested by RT-PCR for HBoV VP1 mRNA, as evidence of active viral replication. HBoV was detected in 4.8% of patients, with annual rates of 10.0%, 3.0% and 3.0% in 2005, 2006 and 2007, respectively. The range of respiratory symptoms was similar between HBoV-positive and HBoV-negative ARI patients. However, a higher rate of diarrhea was observed in HBoV-positive patients. High HBoV viral loads (>108 copies/mL) and diarrhea were significantly more frequent in patients with exclusive infection by HBoV and in patients with detection of HBoV VP1 mRNA than in patients with viral co-infection, detected in 72.9% of patients with HBoV. In summary, our data demonstrated that active HBoV replication was detected in a small percentage of patients with ARI and was correlated with concurrent diarrhea and lack of other viral co-infections
Structure of Anopheles (Diptera: Culicidae) population in areas with different degrees of human settlement: Cantá - Roraima - Brazil
COVID-19, asthma, and biological therapies: What we need to know
Managing patients with severe asthma during the coronavirus pandemic and COVID-19 is a
challenge. Authorities and physicians are still learning how COVID-19 affects people with underlying
diseases, and severe asthma is not an exception. Unless relevant data emerge that
change our understanding of the relative safety of medications indicated in patients with asthma
during this pandemic, clinicians must follow the recommendations of current evidence-based
guidelines for preventing loss of control and exacerbations. Also, with the absence of data that
would indicate any potential harm, current advice is to continue the administration of biological
therapies during the COVID-19 pandemic in patients with asthma for whom such therapies are
clearly indicated and have been effective. For patients with severe asthma infected by SARS-CoV-
2, the decision to maintain or postpone biological therapy until the patient recovers should be a
case-by-case based decision supported by a multidisciplinary team. A registry of cases of COVID-
19 in patients with severe asthma, including those treated with biologics, will help to address a
clinical challenge in which we have more questions than answers
Construction of a competence-based curriculum for internship in obstetrics and gynecology within the medical course at the Federal University of Ceará (Sobral campus)
Fighting Misconceptions to Improve Compliance with Influenza Vaccination among Health Care Workers: An Educational Project
The compliance with influenza vaccination is poor among health care workers (HCWs) due to misconceptions about safety and effectiveness of influenza vaccine. We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination. 398 HCWs were surveyed for adverse events (AE) occurring within 48 h of vaccination. AE were reported by 30% of the HCWs. No severe AE was observed. A subset of 337 HCWs was followed up during four months, twice a week, for the detection of respiratory symptoms. RV was diagnosed by direct immunofluorescent assay (DFA) and real time PCR in symptomatic HCWs. Influenza A was detected in five episodes of respiratory symptoms (5.3%) and other RV in 26 (27.9%) episodes. The incidence density of influenza and other RV was 4.3 and 10.8 episodes per 100 HCW-month, respectively. The educational nature of the present study may persuade HCWs to develop a more positive attitude to influenza vaccination
- …